drugset
Drugs / MiHA-loaded PD-L-silenced DC Vaccination
last change Mar 2021 re-read 3 minutes ago

MiHA-loaded PD-L-silenced DC Vaccination

Cell therapy

Developed for
hematopoietic and lymphoid cell neoplasm
Investigated by
Dutch Cancer Society · Radboud University Medical Center · ZonMw: The Netherlands Organisation for Health Research and Development

Trials 1

today NCT02528682 · Ph 1/2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02528682 Jan 2016 → Mar 2021 hematopoietic and lymphoid cell neoplasm Radboud University Medical Center Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MiHA-loaded PD-L-silenced DC Vaccination ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528682 ↗
Action Inhibit “using siRNA mediated PD-L1/PD-L2 silencing” NCT02528682 ↗
Modality Cell therapy “ex vivo-generated donor DCs loaded with MiHA” NCT02528682 ↗
Route Intravenous “will be infused intravenously” NCT02528682 ↗